Open trial of methotrexate as treatment for autoimmune hearing loss

摘要: Objective To assess the efficacy of low-dose methotrexate (MTX) administered for treatment autoimmune hearing loss. Methods This was a prospective, 12-month, open-label study 17 patients with refractory loss. All had ongoing episodic worsening in one or both ears prior to enrollment despite traditional medical therapy. The MTX dose 7.5–25 mg/week. Hearing loss and vertigo were evaluated at baseline completion study. improvement defined as an pure tone threshold (PT) average >10 dB increase speech discrimination (SD) >15%; decrease PT >15% SD least ear. Results MTX well tolerated. Among Meniere's disease, 5 9 resolution vertigo. Equilibrium improved all 3 Cogan's syndrome 2 out idiopathic this symptom. According parameters above, 11 (65%), unchanged 4 (23%), worsened (12%). Conclusion Long-term therapy may be useful some who have presumptively autoimmune-mediated component that is therapies.